ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

UPC vs TCRT // REVENUE GROWTH (YOY)

Universe Pharmaceuticals Inc. (Class A) (NASDAQ) VS. Alaunos Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: UPC 3 — TCRT 3
▲ REVENUE GROWTH (YOY) LEADER: UPC
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UPC VS. TCRT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC UPC TCRT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 35.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -16.30% -60.00% +43.70 UPC /operating-margins <GO>
Net Profit Margin -20.60% -60.00% +39.40 UPC /net-margins <GO>
Revenue Growth (YoY) ACTIVE -22.40% -50.00% +27.60 UPC /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 TCRT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 23.3 49.1 -25.80 TCRT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $7.7M $7.8M -$65.2K TCRT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR UPC REV TCRT REV UPC GROSS % TCRT GROSS % UPC FCF TCRT FCF
FY 2025 $17.86B $5.0K 35.3% — -$5.32B -$3.0M
FY 2024 $23.02B $10.0K 26.4% — -$9.72B -$5.0M
FY 2023 $32.31B $5.0K — — $1.12B -$30.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UPC // BETA —
TCRT // BETA —